Selective RAR agonists for acne vulgaris: A narrative review

Acne vulgaris is a chronic disfiguring inflammatory disease of adolescents and adults affecting up to 90% of the population around the world. The sequence of etiopathogenesis in acne is not completely understood but involves abnormalities in sebum production, follicular plugging, proliferation of propionibacterium acnes, and chronic inflammation.

[1]  L. Kemény,et al.  Long‐term safety and efficacy of trifarotene 50 μg/g cream, a first‐in‐class RAR‐γ selective topical retinoid, in patients with moderate facial and truncal acne , 2019, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  M. Gooderham,et al.  Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne. , 2019, Journal of the American Academy of Dermatology.

[3]  S. Dogra,et al.  Topical Tazarotene Gel, 0.1%, as a Novel Treatment Approach for Atrophic Postacne Scars: A Randomized Active-Controlled Clinical Trial , 2019, JAMA facial plastic surgery.

[4]  E. Thoreau,et al.  LB1570 Structure-based design of Trifarotene, a potent and selective RAR agonist for the treatment of acne , 2018, Journal of Investigative Dermatology.

[5]  B. Dréno,et al.  Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor‐γ agonist trifarotene , 2018, The British journal of dermatology.

[6]  E. Thoreau,et al.  Structure-based design of Trifarotene (CD5789), a potent and selective RARγ agonist for the treatment of acne. , 2018, Bioorganic & medicinal chemistry letters.

[7]  B. Dréno,et al.  Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison , 2018, American Journal of Clinical Dermatology.

[8]  I. Hassan,et al.  Update on etiopathogenesis and treatment of Acne , 2017, Indian journal of dermatology, venereology and leprology.

[9]  H. Gollnick,et al.  Safety and efficacy of adapalene 0.1% / benzoyl peroxide 2.5% in the long‐term treatment of predominantly moderate acne with or without concomitant medication – results from the non‐interventional cohort study ELANG , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  F. Anjum,et al.  The Historic Panorama of Acne Vulgaris , 2013 .

[11]  H. Williams,et al.  Epidemiology of acne vulgaris , 2013, The British journal of dermatology.

[12]  H. Gollnick,et al.  Synergistic efficacy of adapalene 0.1%-benzoyl peroxide 2.5% in the treatment of 3855 acne vulgaris patients , 2011, The Journal of dermatological treatment.

[13]  N. Kerrouche,et al.  A 6‐month maintenance therapy with adapalene‐benzoyl peroxide gel prevents relapse and continuously improves efficacy among patients with severe acne vulgaris: results of a randomized controlled trial , 2011, The British journal of dermatology.

[14]  C. Lynde,et al.  Treatment of 2,453 acne vulgaris patients aged 12-17 years with the fixed-dose adapalene-benzoyl peroxide combination topical gel: efficacy and safety. , 2010, Journal of drugs in dermatology : JDD.

[15]  Kathy Byrd,et al.  Meeting the Needs and Concerns of Patients With Scalp Psoriasis , 2007, Journal of drugs in dermatology : JDD.

[16]  J. Bikowski.  A new approach to comparing efficacy results from clinical trials of topical acne vulgaris treatments. , 2007, Journal of drugs in dermatology : JDD.

[17]  S. Arsonnaud,et al.  Tolerability comparison of adapalene gel, 0.3% versus tazarotene cream, 0.05% in subjects with healthy skin. , 2007, Journal of drugs in dermatology : JDD.

[18]  N. Burrows,et al.  Acne: more than skin deep , 2006, Postgraduate Medical Journal.

[19]  Sewon Kang,et al.  Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. , 2006, Archives of dermatology.

[20]  A. Shalita,et al.  Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial. , 2006, Journal of drugs in dermatology : JDD.

[21]  J. Herndon,et al.  Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. , 2006, Journal of the American Academy of Dermatology.

[22]  Kenneth E. Homer,et al.  Cumulative irritation potential of adapalene 0.1% cream and gel compared with tazarotene cream 0.05% and 0.1%. , 2005, Cutis.

[23]  R. Alan,et al.  Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. , 2005 .

[24]  Kenneth E. Homer,et al.  Cumulative irritation potential of adapalene 0.1% cream and gel compared with tretinoin microsphere 0.04% and 0.1%. , 2005, Cutis.

[25]  A. Menter,et al.  Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. , 2005, Journal of drugs in dermatology : JDD.

[26]  J. Leyden,et al.  Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. , 2004, Clinical therapeutics.

[27]  N. Dongre,et al.  An open study to evaluate the efficacy and safety of tazarotene gel (0.1%) in acne vulgaris. , 2004, Indian journal of dermatology, venereology and leprology.

[28]  W. Cunliffe,et al.  Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle. , 2003, Journal of the American Academy of Dermatology.

[29]  J. Czernielewski,et al.  Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. , 2003, Journal of the American Academy of Dermatology.

[30]  J. Czernielewski,et al.  Efficacy and cutaneous safety of adapalene in black patients versus white patients with acne vulgaris. , 2002, Cutis.

[31]  M. Lebwohl,et al.  Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. , 2002, Archives of dermatology.

[32]  Y. Poulin,et al.  A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. , 2002, Cutis.

[33]  J. Leyden,et al.  Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. , 2002, Cutis.

[34]  J. Zheng,et al.  A comparison of adapalene gel 0.1% vs. tretinoin gel 0.025% in the treatment of acne vulgaris in China , 2001, Journal of the European Academy of Dermatology and Venereology : JEADV.

[35]  W. Jacyk,et al.  Adapalene in the treatment of African patients , 2001, Journal of the European Academy of Dermatology and Venereology : JEADV.

[36]  J. Jorizzo,et al.  Efficacy and tolerance of adapalene cream 0.1% compared with its cream vehicle for the treatment of acne vulgaris. , 2001, Cutis.

[37]  M. Nighland,et al.  A comparative trial of two retinoids commonly used in the treatment of acne vulgaris , 2001 .

[38]  A. Menter.  Pharmacokinetics and safety of tazarotene. , 2000, Journal of the American Academy of Dermatology.

[39]  D. Tang-Liu,et al.  Clinical Pharmacokinetics and Drug Metabolism of Tazarotene , 1999, Clinical pharmacokinetics.

[40]  A. Shalita,et al.  Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. , 1999, Cutis.

[41]  Meunier,et al.  Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation , 1998, The British journal of dermatology.

[42]  Gilbert,et al.  Comparative tolerance of adapalene 0·1% gel and six different tretinoin formulations , 1998, The British journal of dermatology.

[43]  G. Webster.  Topical tretinoin in acne therapy. , 1998, Journal of the American Academy of Dermatology.

[44]  B. Shroot,et al.  Pharmacology and chemistry of adapalene. , 1997, Journal of the American Academy of Dermatology.

[45]  N. Wagner,et al.  Skin distribution and pharmaceutical aspects of adapalene gel. , 1997, Journal of the American Academy of Dermatology.

[46]  J. Czernielewski,et al.  Adapalene 0.1% gel has low skin-irritation potential , 1997 .

[47]  P. Chambon.  A decade of molecular biology of retinoic acid receptors , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  James T. Elder,et al.  Comparison of CD271 (adapalene) and all-trans retinoic acid in human skin: dissociation of epidermal effects and CRABP-II mRNA expression. , 1993, The Journal of investigative dermatology.

[49]  James T. Elder,et al.  Retinoic acid receptor gene expression in human skin. , 1991, Journal of Investigative Dermatology.

[50]  P. Grimes,et al.  Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. , 2006, Cutis.

[51]  Sewon Kang,et al.  Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. , 2005, Skinmed.

[52]  M Toscano,et al.  [Acne vulgaris]. , 1992, Canadian family physician Medecin de famille canadien.